Total 939 Paclitaxel
related US patents (from
US Patent & Trademark Office)
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
No. 701 - 800 Paclitaxel Patents:
|
PAT. NO. |
|
Title |
701 |
6,048,847 |
 |
Use
of betulinic acid and its derivatives for inhibiting cancer growth
and a method of monitoring this |
702 |
6,048,736 |
 |
Cyclodextrin
polymers for carrying and releasing drugs |
703 |
6,046,234 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
704 |
6,046,230 |
 |
Stable
injection formulation containing paclitaxel |
705 |
6,046,180 |
 |
NAALADase
inhibitors |
706 |
6,046,159 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
707 |
6,043,272 |
|
Withdrawn |
708 |
6,043,249 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
709 |
6,043,072 |
 |
Nucleic
acids encoding Taxus geranylgeranyl diphosphate synthase, and
methods of use |
710 |
6,040,466 |
 |
Taxoids,
their preparation and pharmaceutical compositions containing them |
711 |
6,040,330 |
 |
Pharmaceutical
formulations of taxanes |
712 |
6,040,321 |
 |
Aminothiazole
inhibitors of cyclin dependent kinases |
713 |
6,040,312 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
714 |
6,040,306 |
 |
Method
of treating psoriasis, arthritis and reducing the toxicity of cancer
chemotherapy |
715 |
6,040,304 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
716 |
6,040,294 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
717 |
6,031,133 |
 |
Synthetic
techniques and intermediates for polyhydroxy, dienyl lactones and
mimics thereof |
718 |
6,030,941 |
 |
Polymer
composition for delivering substances in living organisms |
719 |
6,030,818 |
 |
Bacterial
mass production of taxanes and paclitaxel |
720 |
6,028,164 |
 |
Bioresorbable
compositions for implantable prostheses |
721 |
6,028,103 |
 |
Triaryl
methane compounds and analogues thereof useful for the treatment or
prevention of sickle cell disease or diseases characterized by
abnormal cell proliferation |
722 |
6,028,071 |
 |
Purified
compositions of 10-propargyl-10-deazaaminopterin and methods of
using same in the treatment of tumors |
723 |
6,027,711 |
 |
Structurally
determined metallo-constructs and applications |
724 |
6,025,516 |
 |
Resolution
of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13
sidechain of taxanes |
725 |
6,025,488 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
726 |
6,025,365 |
 |
Chelerythrine
and radiation combined tumor therapy |
727 |
6,025,359 |
 |
Drug
resistance and multidrug resistance modulators |
728 |
6,025,345 |
 |
Inhibitors
of NAALADase enzyme activity |
729 |
6,025,344 |
 |
Certain
dioic acid derivatives useful as NAALADase inhibitors |
730 |
6,025,151 |
 |
Uses
for compounds which reduce c-jun gene expression |
731 |
6,020,507 |
 |
Synthesis
of paclitaxel from baccatin III by protection of the 7-hydroxyl of
baccatin III using a strong base and an electrophile |
732 |
6,017,948 |
 |
Water-miscible
pharmaceutical compositions |
733 |
6,017,935 |
 |
7-sulfur
substituted paclitaxels |
734 |
6,015,789 |
 |
Combined
use of GnRH agonist and antagonist |
735 |
6,013,646 |
 |
Indolocarbazole
derivatives useful for the treatment of neurodegenerative diseases
and cancer |
736 |
6,011,021 |
 |
Methods
of cancer treatment using naaladase inhibitors |
737 |
6,008,318 |
 |
Two-stage
solution polymerization of high molecular weight poly(phosphoesters) |
738 |
6,008,007 |
 |
Radiation
resistance assay for predicting treatment response and clinical
outcome |
739 |
6,005,020 |
 |
Bioresorbable
compositions for implantable prostheses |
740 |
6,004,997 |
 |
Trioxane
dimer compounds having antiproliferative and antitumor activities |
741 |
6,004,583 |
 |
Protein-containing
polymer composition for oral administration |
742 |
6,004,573 |
 |
Biodegradable
low molecular weight triblock poly(lactide-co-glycolide)
polyethylene glycol copolymers having reverse thermal gelation
properties |
743 |
6,002,025 |
 |
Method
for the purification of taxanes |
744 |
6,002,024 |
 |
Process
for the isolation of 14.beta.-hydroxy-10-deacetyl baccatin-III |
745 |
6,002,023 |
 |
2-debenzoyl-2-acyl
taxol derivatives and method for making same |
746 |
6,002,022 |
 |
Method
for preparing 4, 10-diacetoxy-2.alpha.-benzoyloxy-5.beta.,
20-Epoxy-1,
7.beta.-dihydroxy-9-oxo-tax-11-en-13.alpha.-yl(2R,3S)-3-benzoylamino-2-h
ydroxy-3-phenylpropionate trihydrate |
747 |
5,998,148 |
 |
Antisense
modulation of microtubule-associated protein 4 expression |
748 |
5,997,904 |
 |
Total
nutrient admixtures as stable multicomponent liquids or dry powders
and methods for the preparation thereof |
749 |
5,994,409 |
 |
Methods
for treatment of neuro--and nephro--disorders and therapeutic
toxicities using aminothiol compounds |
750 |
5,994,367 |
 |
Method
for treating tumors using 2-aryl-naphthyridin-4-ones |
751 |
5,994,341 |
 |
Anti-angiogenic
Compositions and methods for the treatment of arthritis |
752 |
5,994,114 |
 |
Compositions
and methods for taxol biosynthesis |
753 |
5,990,110 |
 |
Method
for treating tumors having high LDL requirements employing MTP
inhibitors |
754 |
5,984,882 |
 |
Methods
for prevention and treatment of cancer and other proliferative
diseases with ultrasonic energy |
755 |
5,981,777 |
 |
Recovery
of taxanes from plant material |
756 |
5,981,564 |
 |
Water-soluble
derivatives of paclitaxel, method for producing same and uses
thereof |
757 |
5,981,279 |
 |
Compositions
and methods to regulate calmodulin gene expression, and uses thereof
for influencing cell growth and differentiation |
758 |
5,977,386 |
 |
6-thio-substituted
paclitaxels |
759 |
5,977,163 |
 |
Water
soluble paclitaxel prodrugs |
760 |
5,973,170 |
 |
C-7
metal alkoxides of baccatin III |
761 |
5,973,163 |
 |
Oxazolidine
carboxylic acid intermediates for esterification of taxanes |
762 |
5,973,160 |
 |
Methods
for the preparation of novel sidechain-bearing taxanes |
763 |
5,969,165 |
 |
Isolation
and purification of paclitaxel and other related taxanes by
industrial preparative low pressure chromatography on a polymeric
resin column |
764 |
5,968,972 |
 |
Method
for increasing the oral bioactivity of pharmaceutical agents |
765 |
5,968,915 |
 |
Naaladase
inhibitors |
766 |
5,968,748 |
 |
Antisense
oligonucleotide modulation of human HER-2 expression |
767 |
5,965,718 |
 |
Analogs
of sarcodictyin and eleutherobin |
768 |
5,965,603 |
 |
Nonaqueous
compositions for parenteral administration |
769 |
5,965,566 |
 |
High
molecular weight polymer-based prodrugs |
770 |
5,962,527 |
 |
Method
and composition for treating cancers |
771 |
5,962,521 |
 |
Hydroxamic
acid derivatives |
772 |
5,955,621 |
 |
Recovery
of Taxanes from conifers |
773 |
5,955,489 |
 |
Taxane
derivatives, the preparation thereof and formulations containing
them |
774 |
5,952,451 |
 |
Solution
polymerization of high molecular weight poly(phosphoesters) in
toluene |
775 |
5,948,919 |
 |
Paclitaxel
synthesis from precursor compounds and methods of producing the same |
776 |
5,945,100 |
 |
Tumor
delivery vehicles |
777 |
5,939,567 |
 |
Synthesis
of hydrophobic taxane derivatives |
778 |
5,939,453 |
 |
PEG-POE,
PEG-POE-PEG, and POE-PEG-POE block copolymers |
779 |
5,935,937 |
 |
Compositions
and methods for inducing apoptosis |
780 |
5,932,758 |
 |
Process
for the production .beta.-amino-.alpha.-hydroxycarboxylic acids and
derivatives thereof |
781 |
5,932,609 |
 |
Pharmaceutical
composition for inhibiting the growth of cancers |
782 |
5,932,604 |
 |
Pharmaceutical
compositions for the treatment of viral infections |
783 |
5,929,099 |
 |
Pharmaceutical
composition for inhibiting the growth of cancers |
784 |
5,928,641 |
 |
Anti-endoglin
monoclonal antibodies and their use in antiangiogenic therapy |
785 |
5,925,776 |
 |
Polyethoxylated
castor oil, process of making the same and formulations thereof |
786 |
5,922,754 |
 |
Pharmaceutical
compositions containing paclitaxel |
787 |
5,922,674 |
 |
Method
of treatment using chemotherapy and erythropoietin |
788 |
5,919,821 |
 |
Use
of boswellic acid for treating brain tumors |
789 |
5,919,816 |
 |
Formulations
and methods of reducing toxicity of antineoplastic agents |
790 |
5,919,815 |
 |
Taxane
compounds and compositions |
791 |
5,919,455 |
 |
Non-antigenic
branched polymer conjugates |
792 |
5,917,062 |
 |
Intermediates
and methods useful in the semisynthesis of paclitaxel and analogs |
793 |
5,917,056 |
 |
10-deacetyl-14.beta.-hydroxybaccactine
III derivatives, a process for the preparation thereof and
formulations containing them |
794 |
5,916,913 |
 |
Inhibition
of wound contraction with paclitaxel, colchicine and penicillamine |
795 |
5,916,596 |
 |
Protein
stabilized pharmacologically active agents, methods for the
preparation thereof and methods for the use thereof |
796 |
5,914,411 |
 |
Alternate
method for acylating 10-deacetylbaccatin III selectively at the C-10
position |
797 |
5,912,346 |
 |
Treatment
and prevention of neoplasms with salts of aminoimidazole carboxamide
and 5-amino or substituted amino 1,2,3-triazoles |
798 |
5,912,264 |
 |
6-halo-or
nitrate-substituted paclitaxels |
799 |
5,912,263 |
 |
Taxane
derivatives |
800 |
5,908,855 |
 |
Compositions
for treating viral infections |
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
|